Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.